Last month, BEL software SOURCERER achieved FDA 510(k) clearance. “FDA clearance of SOURCERER has been a major goal of our team and for the BEL Quality Management System,” said Dr. Don Tucker, CEO and Founder of BEL Company, and of Neurosom. BEL Company was founded in 2017 after a successful sale of a previous company […]
This is a guest blog in collaboration with Nocturnal, a product development firm specializing in Class II and Class III medical devices and offering fixed-price projects to minimize the risk of time and budget overruns. Translating a groundbreaking concept into a commercially viable medical device requires navigating a complex web of challenges, from securing funding […]
5 Questions with MARAbio Founder & Chief Science Advisor, Dr. Judy Van de Water Breakthroughs in the study of a sub-type of autism are powering a new area of precision-medicine to change the future of autism. MARAbio’s pioneering Founder & Chief Science Advisor shares her thoughts on what’s at stake and what’s in store. Guest […]
A market ripe for digital disruption in the 21st century Guest Post by Diana Hall, President and CEO of ActivArmor Fracture care has revolved around one solution for thousands of years: an application by wrapping wet material, like cotton, with plaster or fiberglass that hardens while drying – called “casting.” Throughout history, there have been […]
Guest Post by Michael G. Nathans, CEO and Co-Founder at WhisperSom Corporation Researchers have found that diabetes and ADHD in children as well as heart attacks, strokes, and Alzheimer’s Disease in adults are linked to unmanaged sleep apnea. Why? Because regular breathing while asleep is as important as having a regular heartbeat—and sleep apnea disrupts a person’s […]
Guest Post by Andrew Dahl of NOXBOX Concussions are a mild to moderate traumatic brain injury (TBI) that can have serious long-term effects on the brain. The effects of a concussion can range from mild to severe and can last for days, weeks, or even months. Unfortunately, concussions are often difficult to diagnose. Delayed concussion […]
Funded by multiple grants, alum Russ Lehrman (PhD ‘81) is developing a new therapeutic to revolutionize pulmonary care, starting with preterm infants Guest Post By Brianna Foth Respiratory disease and related complications are a leading cause of illness and death in the United States, collectively costing the health system more than $170 billion annually. Respiratory disease […]
Written by Andrew Dahl, CEO of NOXBOX Concussions are a serious problem in the U.S., but they’re not well understood by the general public. The Centers for Disease Control and Prevention estimates that 7.8 million concussions occur annually in the United States alone, but it’s likely another 7.8 million go unreported. This is a conservative […]
Site Disclaimer
Want to learn more about investing in Regulation Crowdfunding (Reg CF)? Access our investor educational material here.
Important Disclosures
The www.RedCrow.com website (the “Website” or “Site”) is operated by Red Crow Crowd Inc. (“RedCrow”) and owned by Alira Health Transaction Services. Sections of this website are used by Alira Health Transaction Services (FINRA CRD No. 140203), which is a registered broker-dealer and a member of FINRA | SIPC. Information on all FINRA registered broker-dealers can be found on FINRA’s BrokerCheck. All securities-related activity is conducted by Alira Health Transaction Services, located at 1 Grant St, Framingham, Massachusetts 01702. Neither RedCrow or Alira Health Transaction Services provides investment advice or makes investment recommendations on this website; nothing posted on the Site should be construed as such. No communication, through this website or in any other sections of this website or medium should be construed as a recommendation for any security offered on or off this investment platform.
Alternative investments are speculative, involve a high degree of risk and are not suitable for all investors and you should not invest unless you are able to sustain the risk of loss of your entire investment. Complete loss of principal is possible. Private placements are unregistered securities, considered illiquid and long-term investments. Distributions are not guaranteed. Investing in securities involves risks, and there is always the potential of losing money when you invest in securities.
Content provided is for informational purposes only and is not intended to be an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities or a solicitation of any such offer. Information provided does not take into account an investor’s specific objectives or risk profile. Investment decisions should be made based on your objectives and circumstances and in consultation with your own advisors. Alira Health Transaction Services does not provide tax, legal or accounting advice. Please consult with and rely on a qualified professional.
By accessing this website and any pages thereof, you agree to be bound by the Terms of Use.
Form CRS | Regulation Best Interest | Business Continuity Plan | Privacy Policy | Electronic Delivery Consent.
